Alecardio: “Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular Risk in patients with a recent ACS event and type two diabetes mellitus”
Impact: “A multicenter, single-blinded, and randomized clinical trial to demonstrate that early detection of Atrial arrhythmias based on Biotronik Home Monitoring technology combined with a predefined Anticoagulation plan will reduce the rate of the composite end stroke, systemic embolism and major Bleeding”
Promise: “A prospective, phase 4, pragmatic, randomized trial of clinical effectiveness of imaging Strategies, comparing the value of anatomic testing (coronary CT angiography) to functional testing (Exercise ECG, stress nuclear, stress echo)”
Solid: “This is a randomized, placebo-controlled, double-blinded, parallel group, multicenter, event driven Trail. This study is to evaluate clinical efficacy of long-term Treatment with Darapladib Enteric Coated Tablets, 160mg as compared to placebo when added to standard of care in an ACS patient population on the incidence of first occurrence of the composite MACE”
Aleprevent: “A phase 3B study to evaluate the potential of Aleglitzazr to reduce cardiovascular risk in Patients with stable cardiovascular disease and glucose abnormalities”
Improve It: “A multicenter, Double blinded, Randomized study to establish the Clinical benefit and safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk subjects presenting with Acute Coronary Syndrome (Improved Reduction of outcomes: Vytorin Efficacy International Trial”
Novartis CLCZ696B2314: “A multicenter, randomized, double-blinded, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enelapril on mornidity and mortality in patients with chronic heart failure and reduced ejection fraction”
Pegasus: “A randomized, double-blinded, placebo controlled, parallel group, multinational trial to assess the prevention of theombotic events with ticagrelor compared to placeo on a background of acetyl salicylic acid therapy in patients with history of myocardial infarction”
A-HEFT Trial – Bidil Drug StudyThe objective of the African-American Heart Failure Trial (A-HeFT) study was to test if BiDil (H-N), a single tablet fixed combination of 37.5mg hydralazine plus 20mg isosorbide dinitrate added to standard therapy is superior to placebo in improving clinical outcomes of African-American patients with HF.1 A-HeFT is a double-blind, placebo-controlled study involving 600 patients.
Periscope Trial – Diabetes Mellitus Trial Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes:
Acuity Trial Antithrombotic Strategies in Patients With Acute Coronary Syndromes Undergoing Early Invasive Management
Rocket Trial – Atrial Fibrillation for Rivaroxaban The main objective of the ROCKET AF trial was to demonstrate noninferiority of rivaroxaban compared with warfarin for the prevention of stroke or systemic embolism in patients with AF
Avant Garde Trial – a multinational, double-blind trial, randomized 1101 patients stabilized after ACS without clinical evidence of heart failure or left ventricular function
